GENOMIND, INC.
KING OF PRUSSIA, PA

Philadelphia Business Journal Emerging Company of the Year The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes, selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. Ronald I. Dozoretz, MD is the Founder and Chairman of Genomind. He is a recognized national leader and advocate for mental healthcare quality, access, and innovation. He is known for his ability and success in bringing new programs and models of care into clinical practice and the market. He is also the Founder and Chairman of ValueOptions, Inc., one of […] Dr. Jay Lombard is Co-founder and Chief Scientific Officer and Medical Director at Genomind. He is responsible for Genomind’s scientific research and development, as well as medical leadership and clinical oversight. Dr. Lombard is a board certified neurologist. Dr. Lombard has published several books on the role of nutrition and the brain and has lectured extensively on this topic. He […] As President and Chief Executive Officer, Mr. Koffler oversees all aspects of Genomind’s operations. Mr. Koffler joined Genomind in 2011 as the Chief Financial Officer, and was responsible for overall financial management of the company, including financial reporting, financial planning and analysis and corporate and strategic development. Mr. Koffler helped lead Genomind from its commercialization through its recent capital raising […] As Chief Commercial Officer, Mr. Gibbs is responsible for overseeing the overall commercial operations at Genomind including Sales, Account Management, Marketing, and Customer Service. In this role he is responsible for the overall commercialization of Genomind’s Products, raising brand awareness, and implementing all facets of the Genomind technology globally. Mr. Gibbs brings nearly 15 years of experience in leadership roles […] As Senior Vice President and Chief Financial Officer, Mr. Hess is responsible for overall financial management of the company, including financial reporting, financial planning and analysis and corporate and strategic development. Prior to joining Genomind, Mr. Hess was the Chief Financial Officer and Executive Vice President of Keane. Keane is the largest provider of unclaimed property services in the United […] As Senior Vice President and Chief Strategy Officer, Ms. Cummins is responsible for developing and implementing growth plans to optimize revenue. In this role she oversees marketing, U.S. market access and billing operations, business partnerships and international growth. Prior to joining Genomind, Ms. Cummins was VP Market Access and Health Policy for Ariosa Diagnostics (acquired by Roche Diagnostics), where she was responsible for […] Dr. David Krause is Chief Medical Officer at Genomind with more than 25 years of experience in pharmaceutical research and development and medical affairs. As Chief Information Officer, Mr. Levine is responsible for all aspects of Genomind’s information technology, services and operations, and for leading the IT team to deliver solutions that enable business strategies. Mr. Levine has over twenty years of experience in information technology, specializing in leading and developing new technologies in emerging healthcare markets. As Director of Applications Architecture for Health […] Dr. Robbins serves as the Senior Vice President of Molecular Pathology and the Laboratory Director, and is responsible for all aspects of laboratory operations at Genomind. Dr. Robbins has extensive experience in clinical molecular diagnostic testing in the fields of genetics, oncology and infectious diseases. Prior to joining Genomind, he founded the nucleic acids testing division of UTC Labs. He […] An author of over 425 articles and more than 1500 scientific presentations and abstracts, Dr. Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited five books and written 25 more, including the best-selling textbook Stahl’s Essential Psychopharmacology, now in its third edition, and the best-selling clinical manual, Essential Psychopharmacology […] Trio of Awards Cap Ground-Breaking Year for Genomind and Its Unique Platform More Americans Than Ever Embrace Genetic Testing To Aid In Mental Health Treatment, According To Annual Genomind® Mental Health Poll™ Thank you for considering our employment opportunities. Genomind is an Equal Opportunity and Affirmative Action Employer as well as a Drug Free Work Environment. Genomind offers a competitive benefits program including: We appreciate your interest in Genomind. If you have questions or feedback about our company or products, please get in touch with us using the form below or through our contact information on the bottom left. If you would like to receive interesting news about our products, personalized medicine, biomarker testing in psychiatry, or pharmacogenetics, be sure to check the box at the bottom of the form. Philadelphia Business Journal Emerging Company of the Year The Genecept Assay® is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patient-specific genetic markers that indicate which treatments are likely to work as intended, have no effect, or cause adverse effects. It is an easily administered cheek swab test that analyzes key genes, selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The complexity of biological systems is astounding, and to us at Genomind, this means understanding and treating the whole person as something much greater than the sum of his or her parts.